Chairman + CEO

Anthony P. Mack has more than 25 years of experience in the pharmaceutical and finance industries. Prior to founding VIRPAX in 2016, Mr. Mack founded SCILEX Pharmaceuticals and served as President and CEO until ZTlido was approved in February 2018. Mr. Mack founded his first pharmaceutical company ProSolus Pharmaceuticals in 2009, where he served as President before selling the company to Mission Pharmacal in 2015. Mr. Mack has held high-level management positions with Purdue Pharma, Endo Pharmaceuticals, Novartis, and EKR Therapeutics. He has led training, marketing, and commercial distribution for billion-dollar pain management products and has forged key strategic alliances. Mr. Mack has served as Founder, Director, and Executive Officer of both ProSolus Pharmaceuticals Inc. and SCILEX Pharmaceuticals. After SCILEX’s lead product, ZTlido, was approved for commercialization by the FDA, SCILEX was sold to a publicly traded company. Mr. Mack also founded and serves as Director of IACTA Pharmaceuticals Inc. By serving on executive boards, Mr. Mack has utilized his skills and experience to implement policies relating to corporate governance and overall business strategy. Mr. Mack holds an Executive MBA in Pharmaceutical and Healthcare Marketing from Saint Joseph’s University.